April 15, 2014
For More Information, Contact: Michele Scrofani, Vice President HQ Specialty Pharma, LLC 201.857.8290     Paramus, NJ, April 15, 2014 – HQ Specialty Pharma and its collaborating partner, WelGrace Research Group, have received tentative approval on its 505(b)(2) application for Esmolol Hydrochloride Premixed Injection, which references Brevibloc® Injection. The product will be available in two...
Read More
© 2023 WG Critical Care, LLC | A PharmaSphere Company | 120 Rte 17 N, Paramus, NJ 07652